$151.83
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Country

US

CEO

Mr. Robert Davis

IPO date

1941

Employees

75,000

ISIN

US58933Y1055

Key stats

Open

$149.88

Volume

16.43M

Market cap

$367.58B

Prev. close

$148.99

Impl / hst vl

-

Open interest

$0.00

$148.59

Day’s Range

$154.49

$104.43

52W Range

$153.50

Valuation

16
Valuation score
Strongly Overvalued
P/E
103.86
P/S
4.95
P/B
7.18
Current ratio
-
Debt / Equity
1.07
ROE
-
Gross margin
81.07%
Income growth
-68.51%
FCF growth
-

Oct

7

Dividends

The next payment date will be Oct 7, 2026

Div. per Share

$0.85

Div. Yield

0.57%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 16 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$135.65
The top 31 analysts forecasts that 12-month price may decrease by 10.66%, with a low of $101.00 and a high of $162.75
$101.00
Low
$135.65
Avg
$162.75
High
Current price

Earnings

Q2 ‘26 revenue
$16.61B
Q2 ‘26 net income
-$1.34B
Revenue
Net income
Previous EPS
-$1.28
Estimate EPS
-$0.27
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply